In 564 patients with MRI-defined locally advanced rectal cancer, adding irinotecan to preoperative capecitabine chemoradiotherapy did not improve 36-month disease-free survival (68% vs 67%; HR 0·91, p=0·54) and raised grade 3+ toxicity (78% vs 52%).
RCTn = 589
Sebag-Montefiore et al. Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial